Smith & Nephew (LON:SN) Given Sector Perform Rating at Royal Bank Of Canada

Royal Bank Of Canada reissued their sector perform rating on shares of Smith & Nephew (LON:SN) in a report issued on Tuesday,London Stock Exchange reports. They currently have a GBX 1,350 price objective on the stock.

SN has been the subject of a number of other research reports. Berenberg Bank reiterated a “hold” rating and issued a GBX 1,300 price objective on shares of Smith & Nephew in a report on Friday, January 23rd. Panmure Gordon reiterated a “hold” rating and issued a GBX 1,200 price target on shares of Smith & Nephew in a research note on Tuesday, December 9th. Two analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of GBX 1,381.33.

Smith & Nephew Stock Performance

Shares of LON SN remained flat at GBX 1,251.50 during midday trading on Tuesday. 1,618,325 shares of the company traded hands, compared to its average volume of 343,671. The stock has a market capitalization of £13.72 billion, a P/E ratio of 45.06, a price-to-earnings-growth ratio of 0.46 and a beta of 0.68. The company has a 50 day moving average of GBX 1,273.26 and a 200-day moving average of GBX 1,295.49. The company has a debt-to-equity ratio of 62.90, a current ratio of 2.57 and a quick ratio of 0.84.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.